Eye Diseases D005128

Diseases [C] » Eye Diseases

Description

Diseases affecting the eye.   MeSH

Subtype Terms (26)

Asthenopia
5 experimental drugs

Cogan Syndrome
3 approved drugs

Conjunctival Diseases
3 drugs (1 approved, 2 experimental)

Corneal Diseases
101 drugs (52 approved, 49 experimental)

Eye Abnormalities
1 experimental drug

Eye Diseases, Hereditary
31 drugs (17 approved, 14 experimental)

Eye Hemorrhage
 

Eye Infections
11 drugs (8 approved, 3 experimental)

Eye Injuries
2 experimental drugs

Eyelid Diseases
8 drugs (7 approved, 1 experimental)

Eye Manifestations
1 approved drug

Eye Neoplasms
7 drugs (4 approved, 3 experimental)

Lacrimal Apparatus Diseases
14 drugs (7 approved, 7 experimental)

Lens Diseases
6 drugs (5 approved, 1 experimental)

Ocular Hypertension
91 drugs (36 approved, 55 experimental)

Ocular Hypotension
 

Ocular Motility Disorders
3 approved drugs

Optic Nerve Diseases
5 drugs (4 approved, 1 experimental)

Orbital Diseases
2 drugs (1 approved, 1 experimental)

Pupil Disorders
3 approved drugs

Refractive Errors
19 drugs (16 approved, 3 experimental)

Retinal Diseases
100 drugs (60 approved, 40 experimental)

Scleral Diseases
 

Uveal Diseases
3 approved drugs

Vision Disorders
26 drugs (13 approved, 13 experimental)

Vitreous Detachment
9 drugs (8 approved, 1 experimental)



Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.